Methods of coronary imaging
View Patent ↗The present invention provides methods of myocardial perfusion imaging and increasing coronary blood flow of a mammal that are accomplished by administering doses of a compound that is a selective partial A 2A receptor agonist with a short duration of action, in particular regadenoson, useful for, among other indications, myocardial imaging and coronary vasodilation, and determining areas of insufficient blood flow.
1. A method of myocardial perfusion imaging of a mammal in need thereof, comprising administering an imaging agent comprising a radionuclide and a dose of a compound that is CVT-3146, also known as (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide to a mammal in need thereof, and determining areas of insufficient blood flow, wherein the dose is from 0.3 to 103.0 μg/kg, and wherein the dose causes an increase in peripheral blood flow that is less than 50% of the increase in coronary blood flow.
2. The method of claim 1 , wherein the dose of CVT-3146 is from 0.3 to 10.0 μg/kg.
3. The method of claim 1 , wherein the step of administering the dose of CVT-3146 takes place by a bolus injection of a pharmaceutically acceptable composition thereof.
4. The method of claim 1 further comprising dissolution of CVT-3146 in a pharmaceutically acceptable liquid carrier to form a pharmaceutically acceptable liquid composition.
5. The method of claim 1 wherein the CVT-3146 compound is administered in a single dose.
6. The method according to claim 1 wherein the dose is administered immediately prior to or concurrently with the imaging agent.
7. The method according to claim 6 wherein the CVT-3146 compound is administered at the same time as the imaging agent.
8. The method according to claim 6 wherein the CVT-3146 compound is administered before the imaging agent is administered.
9. A method for increasing coronary blood flow in a mammal in need thereof comprising administering a pharmaceutically effective amount of a compound that is CVT-3146, also known as (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, wherein the pharmaceutically effective amount is from 0.3 to 103.0 μg/kg, and wherein the administration causes an increase in peripheral blood flow that is less than 50% of the increase in coronary blood flow.
10. The method of claim 9 , wherein the pharmaceutically effective amount of CVT-3146 is from 0.3 to 10.0 μg/kg.
11. The method of claim 9 , wherein step of administering the pharmaceutically effective amount of the CVT-3146 compound takes place by a bolus injection of a pharmaceutically acceptable composition thereof.
12. The method of claim 9 further comprising dissolution of CVT-3146 in a pharmaceutically acceptable liquid carrier to form a pharmaceutically acceptable liquid composition.
13. The method of claim 9 wherein the administration of the CVT-3146 compound takes place in a single dose.